Clarivate Scales Agentic AI Across Cortellis Portfolio to Accelerate Drug Development Decisions
核心洞察
Clarivate announced the expansion of agentic AI capabilities across its Cortellis portfolio to help life sciences R&D teams accelerate discovery, strengthen safety assessment, and make faster portfolio decisions.
New capabilities in Cortellis Drug Discovery Intelligence enable researchers to evaluate therapeutic landscapes and compare compounds using natural language queries.
Enhanced OFF-X multi-agent intelligence helps safety teams surface potential liabilities earlier and support proactive risk evaluation across development and post-market activities.
Clarivate Plc (搜索), a leading global provider of transformative intelligence, today announced the expansion of agentic AI capabilities across its Cortellis portfolio, a move designed to help life sciences R&D teams accelerate discovery, strengthen safety assessment, and make faster, more informed portfolio decisions. By embedding AI directly within existing workflows, the new capabilities enable researchers to reduce manual effort, navigate complexity, and focus on higher-value scientific and strategic decisions.
The announcement, made from London on August 6, 2026, marks a significant evolution of the Cortellis suite from a trusted information source into what the company describes as a connected ecosystem of agentic capabilities that augment human expertise across the R&D lifecycle.
Accelerating Discovery Decisions
New capabilities within Cortellis Drug Discovery Intelligence enable researchers to engage with complex drug intelligence through natural language, rapidly evaluate therapeutic landscapes, compare compounds and targets, and prioritize promising opportunities. By reducing time spent gathering and synthesizing information, teams can focus more of their expertise on advancing the most compelling paths forward.
Advancing Proactive Safety Assessment
Enhanced capabilities within OFF-X introduce multi-agent intelligence that helps safety teams surface potential liabilities earlier, synthesize evidence more efficiently, and support more proactive risk evaluation across development and post-market activities. These capabilities strengthen safety assessment while improving consistency and productivity, according to the company.
Strengthening Competitive and Portfolio Strategy
New agentic workflows within Cortellis Competitive Intelligence help strategy and business development teams monitor evolving markets, assess competitive dynamics, and evaluate external growth opportunities. The company reports that these tools transform weeks of manual analysis into actionable intelligence delivered in hours.
Anne Lecocq, Senior Vice President and General Manager, R&D, Life Sciences & Healthcare at Clarivate, emphasized the strategic importance of the development: "In modern R&D, success depends on how quickly teams can translate complex data into decisive action. Cortellis is advancing this shift with agentic AI, evolving from insight delivery to workflow execution across the product lifecycle."
Lecocq added: "Together, these innovations reflect the evolution of Cortellis from a trusted information source into a connected ecosystem of agentic capabilities that augment human expertise across the R&D lifecycle. Built on trusted data, it empowers teams to reduce friction, align decisions and act with precision in high-stakes environments."
The Cortellis suite combines proprietary data, expert curation, and embedded AI to help R&D, portfolio strategy, business development, and regulatory professionals act on intelligence across the drug development lifecycle. The latest AI capabilities span three critical areas: discovery, safety, and portfolio strategy, reflecting the growing industry demand for AI-driven decision support tools that can keep pace with the increasing complexity of pharmaceutical R&D.